Factor V is the liver-synthesized multidomain glycoprotein encoded by a gene localised on chromosome q. Th e point mutation G>A in this gene results in formation of an altered protein of V Factor resistant to activated protein C (APC) cleavage. Th is mutation alone is the most frequent cause of inborn thrombophilia and the most widely acknowledged genetic risk factor for venous thrombosis in a Caucasian population. Th is study was designed to provide the fi rst estimate of the frequency of the allele A FV in the Bosnian female population. Th e G>A FV mutation was examined by polymerase chain reaction-restriction fragment length polymorphism, in a group of  women, mean age of . years with no history of cardiovascural incident. Our fi ndings revealed an absence of the mutated allele A FV in the studied group. Th is is the fi rst report on the G>A FV mutation in a population from Bosnia and Herzegovina. Further research is needed to establish prevalence of the mutated allele in the population from Bosnia and Herzegovina.
INTRODUCTION
Inherited resistance to activated protein C (APC) is one of the most common genetic defects associated with familial thrombophilia and is now known to be the most common genetic risk factor for venous thrombosis. It is an autosomal dominant disorder caused by a single point mutation in the Factor V gene, which predicts substitution of arginine (R) to a glutamine (Q) at aminoacid position . G>C transition ocures at nucleotide position  located in exon . Th is mutation is known as Factor V Leiden (FVL) [] . Factor V Leiden, in comparision with the active form, is inactivated by protein C at a much slower rate. Since mutated Factor V is resistant to the anticoagulative action of protein C, it cannot be activated by cleavage, causing inactivation of the antithrombotic regulatory pathway [-] . Carriers of G>A FV are more likely to develop abnormal blood clots, which in extreme cases can cause deep vein thrombosis (DVT), pulmonary embolism and superficial thrombophlebitis.
Furthermore, mutation G>A of the gene coding for Factor V accounts for the most common cause of inherited predisposition to thrombosis. It has been reported that, presumably due to placental thrombosis, Factor V Leiden increases by -to -fold the risk for recurrent miscarriage and possibly other obstetrical complications such as intrauterine growth restriction and placental abruption [-] . The  G>A FVmutation in fertile women might be associated with deep vein thrombosis and pulmonary embolism during pregnancy, increased risk of preeclampsia, recurrent miscarriage and placental development. During postmenopausal period, estrogen replacement therapy is associated with imbalance in coagulation and fi brinolysis especially relevant for G>A FV mutation carriers. It is known that the frequency of the G>A FV allele varies worldwide and differences are observed between geographic locations and ethnic populations. Recent studies have concluded that the G>A mutation is virtually nonexistent in Asia and in some regions of Africa; however, the mutation showed a higher prevalence in the Lebanese population (.) and was extremely high among healthy Palestinians (.) [-] . In Europe the G>A FV provides a mosaic, among South-Eastern European countries the frequency of allele A FV varied from . in Bulgaria, . in Macedonia, . in Serbia to . in Croatia, indicating an upward trend in Southeasterly direction [] . Multiple data is available in most of Europe; however, no accurate data show any degree of prevalence for Bosnia and Herzegovina. Since women might be more susceptible to present with complications due to Factor V Leiden both during the fertile and postmenopausal period the purpose of this study was to show the prevalence of G>A FV mutation in females from Bosnia and Herzegovina and to evaluate whether the prevalence of FV G>A was consistent with the results from other studies carried on female population.
MATERIALS AND METHODS

Subjects
For the study purposes  apparently healthy females (mean age . y, range: from  to  y) were enrolled. None of the subjects included in the study reported previous history of deep vein thrombosis, pulmonary embolism or superficial thrombophlebitis. Sample collection was focused on the oral cavity. Buccal swabs were collected at the Laboratory for Molecular Medicine, Center for Genetics, Faculty of Medicine, University of Sarajevo. Written consent was obtained from each individual enrolled in this study. The local ethical committee approved the protocol of the study.
Methods
Following DNA isolation from buccal swabs (PrepFilerTM Forensic DNA Extraction Kit, Life Technologies, USA) the polymerase chain reaction-restriction fragment length polymorphism G>A FV was performed. For a  μL PCR, ~ ng of genomic DNA was used. Th e PCR mixture contained x PCR Buff er (pH ., . mM MgCl), . mM each of the deoxynucleoide triphosphates, . U AmpliTaq®DNA Polymerase (Roche) and  pmol each of the forward and reverse primers as designed by Gandrille et al. [] . PCR reactions were performed in a Mastercycler® pro with vapo protect device (Eppendorf, Germany) with the following temperature profi les: initial denaturation at ˚C for  min,  cycles of  s at ˚ C,  s at ˚ C and  s at ˚C; and fi nal extension step at ˚C for  min. Amplifi cation was followed by digestion of a  bp product with Hind III restriction enzyme ('-AAGCTT-') (MBI Fermentas, Lithuania) for  hours at ˚C. Th e restriction fragments were visualized after electrophoresis in   agarose gels, stained with Sybr® Green (Apllied Biosystems, USA). Hind III digestion yields fragment of  bp (homozygote GG), ,  and  bp (heterozygote GA) and ,  bp (homozygote AA).
RESULTS
The results obtained in this study, which included  healthy women, reveal that the A allele was absent.
DISCUSSION
The G>A FV variant has been described as a common genetic risk factor in thrombophilia and pulmonary embolism. Previously we provided a summary study of the frequency distribution of G>A FV including the whole of Europe by addition of values from  Slavic countries [] . Our findings revealed in upward trend Southeasterly direction in allele A FV, from Croatia (.), Serbia and Montenegro (.), Slovenia (.) to Bulgaria (.) [] . However, there were no data on the frequency of A FV in Bosnia and Herzegovina. Th is has prompted us to investigate the prevalence of this mutation in this country. To our knowledge we give the first study on the subject. Th e results presented here reveal that in the group of  Bosnian woman the A allele was absent. In Bulgarian women Factor V Leiden was more prevalent in the group of women with fetal loss (.) compared to the healthy women (.) [] . In Polish women FVL in a cohort of  women with a history of at least two miscarriages was . while in the control group consisting of  women without obstetric complications was found to be . [] . The Hordaland homocysteine study from Norway reported the G>A FV to be . in females [] . A study from Germany reported the prevalence of the Factor V Leiden to be equally high in the group of women with recurrent abortions (/; .) compared with the control group (/; .) [] . In Greek women  of  recurrent miscarriage patients and  out of  controls carried the Factor V Leiden mutation ( vs. ) [] . A study from France reported the Factor V Leiden distribution was / (.) which was significantly higher than the Factor V than in the control women (/ (.) [] . In North American women G>A mutation was . in Caucasian women (N=) and . (N=) in African Americans women [] . A study from US compared prevalence of FV mutation in  nonpregnant women with three or more pregnancy losses and  healthy nonpregnant controls. G>A FV mutation was observed in  () women with pregnancy loss and was not statistically significantly diff erent from controls [] . A study on Israeli women with recurrent miscarriages revealed the G>A mutation in / women (.) and / (.) in healthy controls [] . In Lebanese women with primary habitual abortion,  (.) carried the FV Leiden, compared to . carrier rates among controls [] . In Palestinian women the G>A FV mutation was detected in  of the  women with recurrent miscarriages (.), and in  of the  control healthy women (.) [] . The prevalence of Factor V Leiden in Turkish women with recurrent pregnancy loss was . (/) compared with  (/) in the control group [] . In Iranian women the prevalence of FVL in the healthy women group was . [] . Th ese preliminary results of the presence of G>A mutation in the Bosnia and Herzegovina raise the question of future screening for this mutation, including both genders.
